Bluejay Diagnostics, Inc. (BJDX) vs China SXT Pharmaceuticals, Inc. (SXTC)

A side-by-side comparison of Bluejay Diagnostics, Inc. and China SXT Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BJDX

Bluejay Diagnostics, Inc.

$843188

$0.81HealthcareDelayed quote: Oct 6, 2026, 2:03 PM EDT

SXTC

China SXT Pharmaceuticals, Inc.

$795623

$1.49HealthcareDelayed quote: Oct 6, 2026, 2:04 PM EDT

Total return — BJDX vs SXTC

growth of $100 · dividends reinvested · last 5y

BJDX -100.0% (-91.1%/yr)SXTC -100.0% (-95.2%/yr)BJDX compounded faster over this window

Log scale — wide-divergence pair

BJDX SXTC

Metrics side by side

Total return (annualized)

Metric	BJDX	SXTC
Total return (1Y)	-87.52%	N/A
Total return CAGR (3Y)	-95.06%	N/A

SXTC is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full BJDX analysis Full SXTC analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.